XSHG
600200
Market cap124mUSD
Nov 25, Last price
1.24CNY
Name
JiangSu WuZhong Pharmaceutical Development Co Ltd
Chart & Performance
P/E
12.51
P/S
0.55
EPS
0.10
Div Yield, %
—
Shrs. gr., 5y
-0.34%
Rev. gr., 5y
-5.40%
Revenues
1.60b
-28.64%
Net income
70m
P
CFO
-275m
L+34.85%
Dividend
Jun 15, 20180.056 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
JiangSu WuZhong Pharmaceutical Development Co., Ltd., together with its subsidiaries, engages in pharmaceutical, real estate, and chemical businesses in China. It develops, produces, and sells anti-infective, digestive system, cardiovascular, cerebrovascular, antiviral, vitamin, and hemostatic drugs; and immunomodulations, including biopharmaceuticals, chemical drugs, and modern Chinese medicines. The company offers its products in various forms, such as infusion solutions, water and powder injections, capsules, granules, tablets, emulsions, and oral liquids. It also engages in the research, development, production, and sale of dyes and dye intermediates; and the fields of commercial housing and affordable housing development. The company was founded in 1994 and is based in Suzhou, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||